RxDoctor Payments Data

Sudhir Malik, MD

Neurology · San Diego, CANPI 1801884523

Payments from drug & device makers

$1,315in general payments, 2019–2025

Across 50 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$352
  • UCB, Inc.$250
  • EMD Serono, Inc.$125
  • AbbVie$109
  • Novartis$102
  • Neurelis, Inc.$86
  • plus $290 from 9 others

What the payments were for

  • Food & beverage$1,28898%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,315 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$215,034
Medicare patients
321
Services billed
10,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GilenyaFingolimod Hcl11$114,791
Avonex (4 Pack)Interferon Beta-1a12$112,918
IngrezzaValbenazine Tosylate11$91,812
RytaryCarbidopa/Levodopa25$38,997
Aimovig AutoinjectorErenumab-Aooe40$28,252
QuliptaAtogepant21$23,003
UbrelvyUbrogepant18$16,292
Lacosamide34$16,019
BriviactBrivaracetam11$15,359
Rasagiline Mesylate21$7,646
Memantine Hcl166$6,285
Levetiracetam170$5,927
Carbidopa-LevodopaCarbidopa/Levodopa194$5,075
Rivastigmine18$4,265
Memantine Hcl ErMemantine Hcl35$3,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisGilenya$102$114,79111 claims
BiogenAvonex (4 Pack)$352$112,91812 claims
Neurocrine Biosciences, Inc.Ingrezza$56$91,81211 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$73$43,32958 claims
AbbVieQulipta, Ubrelvy$109$39,29639 claims
UCB, Inc.Briviact$250$15,35911 claims
Lilly USA, LLCOlanzapine$22$82915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →